<DOC>
	<DOCNO>NCT00070655</DOCNO>
	<brief_summary>This trial include patient heart condition call atrial fibrillation . Atrial fibrillation abnormal rhythm ( irregular beat ) heart . Patients atrial fibrillation increase chance blood clot form heart move blood vessel body cause obstruction . This obstruction may damage tissue . For example , blood clot plug vessel brain could cause stroke . Therefore , patient atrial fibrillation may give anticoagulant ( blood-thinning ) tablets warfarin acenocoumarol . The purpose study compare safety effectiveness new injectable anticoagulant drug administer weekly , SR34006 warfarin acenocoumarol tablet . Assignment either SR34006 Injection vitamin K antagonist ( warfarin acenocoumarol ) tablets purely chance know patient doctor .</brief_summary>
	<brief_title>Evaluating Use SR34006 Compared Warfarin Acenocoumarol Patients With Atrial Fibrillation ( AMADEUS )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>SANORG 34006</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Acenocoumarol</mesh_term>
	<criteria>ECGdocumented atrial fibrillation ( AF ) indication longterm vitamin K antagonist ( VKA ) therapy base presence least one follow risk factor : 1. previous ischemic stroke , transient ischemic attack ( TIA ) systemic embolism 2. hypertension require drug treatment 3. leave ventricular dysfunction ( left ventricular ejection fraction &lt; 45 % symptomatic congestive heart failure ) 4. age &gt; 75 year 5. age 6575 year plus diabetes mellitus , 6. age 6575 year plus symptomatic coronary artery disease ( previous myocardial infarction ( MI ) angina pectoris ) Written inform consent Legal low age limitation ( country specific ) Indication VKA AF , include prosthetic heart valve , venous thromboembolism , plan cardioversion Transient AF cause reversible disorder Active bleeding high risk bleed Recent ( &lt; 15 day ) anticipate invasive procedure potential uncontrolled bleeding , include major surgery Participation another pharmacotherapeutic study within prior 30 day Creatinine clearance &lt; 10 mL/min , severe hepatic disease , bacterial endocarditis Uncontrolled hypertension : systolic blood pressure &gt; 180 mm Hg and/or diastolic blood pressure &gt; 110 mm Hg Pregnancy childbearing potential without proper contraceptive measure Breastfeeding Any contraindication list label warfarin acenocoumarol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>